OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
13 Jun 2020
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myelo...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
13 Jun 2020
AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory mu...
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
13 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior l...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Patient reported outcomes for the CANDOR trial for multiple myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple mye...
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
11 Jun 2020
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients wit...
Prof Lionel Ades - Hôpital Saint-Louis, Paris, France
11 Jun 2020
Timing of response to venetoclax combination treatment in older patients with ac...
Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sac...
3 Jun 2020
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple mye...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
1 Jun 2020
